23andMe cuts 40% of its workforce and discontinues therapeutics division
Back in September, all of 23andMe’s independent directors also resigned from its board — in a rare move that followed drawn-out negotiations with Wojcicki, who has been trying to take the company private. The seven resigning directors said they had yet ...
Me is laying off 40% of its workforce right before the holiday season - The restructuring arrives during a period of turmoil ...
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
In addition to workforce reductions, 23andMe has also decided to discontinue its therapeutic ... The situation worsened in ...
Back in September, all of 23andMe’s independent directors also resigned from its board — in a rare move that followed ...
On Tuesday, Wojcicki announced the new additions to 23andMe’s board: Andre Fernandez, a former CFO at WeWork, Inc., and NCR ...
23andMe's CEO called the decision to lay off 200 employees ... The suffering company faced another blow in September when its board of directors resigned. The board’s seven members quit after ...
In September, independent directors of the Board of 23andMe sent a letter to Anne Wojcicki, Chief Executive Officer, Co ...
Genetic testing company 23andMe has appointed three new independent directors to its board, including former WeWork CFO Andre ...
Shares were hovering below $1 until 23andMe announced a 1-for-20 reverse stock split in October. In September, all seven of ...
In another blow to the company, seven of 23andMe’s eight-strong board resigned in September. The firm's independent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback